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Abstract
Background: Interstitial lung disease is a frequent complication in sickle cell disease and is characterized by vascular
remodeling and interstitial fibrosis. Bone marrow-derived fibrocytes have been shown to contribute to the pathogenesis of
other interstitial lung diseases. The goal of this study was to define the contribution of fibrocytes to the pathogenesis of
sickle cell lung disease.
Methodology/Principal Findings: Fibrocytes were quantified and characterized in subjects with sickle cell disease or
healthy controls, and in a model of sickle cell disease, the NY1DD mouse. The role of the chemokine ligand CXCL12 in
trafficking of fibrocytes and phenotype of lung disease was examined in the animal model. We found elevated
concentration of activated fibrocytes in the peripheral blood of subjects with sickle cell disease, which increased further
during vaso-occlusive crises. There was a similar elevations in the numbers and activation phenotype of fibrocytes in the
bone marrow, blood, and lungs of the NY1DD mouse, both at baseline and under conditions of hypoxia/re-oxygenation. In
both subjects with sickle cell disease and the mouse model, fibrocytes expressed a hierarchy of chemokine receptors, with
CXCR4 expressed on most fibrocytes, and CCR2 and CCR7 expressed on a smaller subset of cells. Depletion of the CXCR4
ligand, CXCL12, in the mouse model resulted in a marked reduction of fibrocyte trafficking into the lungs, reduced lung
collagen content and improved lung compliance and histology.
Conclusions: These data support the notion that activated fibrocytes play a significant role in the pathogenesis of sickle cell
lung disease.
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Introduction
Sickle cell disease (SCD) is the most common monogenic
inherited disorder in African-Americans [1]. The two most
common complications of SCD, vaso-occlusive pain crises
(VOC) and acute chest syndrome (ACS), are the major risk
factors for the development of interstitial lung disease (ILD) [2], a
risk for morbidity and mortality in patients with SCD [2,3]. ILD is
characterized by parenchymal and vascular remodeling among
patients with SCD and has been associated with the development
of pulmonary hypertension and, potentially through this mecha-
nism, with increased mortality [2,4]. Although most studies of
SCLD have focused on vascular remodeling and pulmonary
hypertension [5], patients with SCD have long been recognized to
develop a progressive restrictive ventilatory defect and interstitial
markings on chest radiographs [2,6,7]. While many adults with
SCD do not exhibit all features of SCLD, a restrictive pattern on
pulmonary function tests is the most consistent clinical feature; for
example, 74% of adults in a large prospective cohort study SCD
had restrictive lung disease [6]. These studies underscore the need
to better understand the pathogenesis of ILD in patients with
SCD.
Fibrotic lung diseases are associated with dysregulated repair in
response to persistent or recurrent injury, leading to loss of
alveolar-capillary basement membrane integrity and remodelling
of the lung airpace, interstitial and vascular compartments
[8,9,10,11,12]. The fibroblasts involved in this process are known
to be derived, in part, from proliferation of resident lung
fibroblasts. More recent evidence has implicated a bone
marrow-derived circulating mesenchymal progenitor cell, the
fibrocyte, in lung fibrosis and has changed the perspective of lung
repair [13,14,15]. Fibrocytes express the hematopoietic stem cell
antigen CD34, the common leukocyte marker CD45, the myeloid
markers CD11b and CD13, and fibroblast markers vimentin,
collagen I, collagen III and fibronectin, as well as several
chemokine receptors [16,17,18]. Only a subset of circulating
fibrocytes expresses CD34, and the expression of both CD34 and
CD45 on fibrocytes decreases when the cells are cultured or after
they enter tissue. Since there is no single marker unique for the
identification of fibrocytes, the co-expression of collagen produc-
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cells [16,17,18]. Fibrocytes are important in mediating pulmonary
fibrosis in murine models of lung injury [7,13,19,20,21,22] and are
elevated in the blood and lungs of patients with idiopathic
pulmonary fibrosis (IPF) [23,24,25]. Moreover, the number of
circulating fibrocytes is a predictor of prognosis in patients with
IPF [25]. Given the role of fibrocytes in the pathogenesis of lung
remodelling in other diseases, we postulated that these cells are
important in the development of ILD in patients with SCD.
Methods
Peripheral blood samples from adult patients with SCD or race-
matched controls and bone marrow, blood and lungs of NY1DD
mice or congenic C57BL/6 mice were processed for quantification
and characterization of fibrocytes, as previously described [19,23]
(See the online supplement for additional details of methods used).
In some experiments, animals were exposed to hypoxia-reox-
ygenation (3 h at 8% oxygen/92% nitrogen followed by 4 h at
21% oxygen/79% nitrogen) before tissue harvest. CXCL12 was
neutralized in vivo as previously described [13,26]. Lung
mechanics of animals were assessed by FlexiVent using Quasi-
static pressure-volume (PV) curve to calculate total lung compli-
ance and elastance, and forced oscillatory measurements to
measure frequency dependence of parenchymal tissue impedance
and parenchymal tissue elastance according to manufacturer’s
instructions. Plasma samples were analyzed for cytokines by
Luminex multiplex protein analysis as previously described [13].
Lung collagen content was quantified using the Sircol assays
(Biocolor Ltd., Belfast, United Kingdom) according to the
manufacturer’s instructions [27] and using morphometric analysis
of histological samples after picrosirius red staining [28]. To
quantify picrosirius red stains, lungs were inflated, fixed and
sectioned; photomicrographs were then obtained from 10
randomly selected medium power fields from the lung periphery
in each slide. By obtaining images from the lung periphery only,
we excluded fields that included large blood vessels or airways. In
human subjects, fibrocyte concentrations were not distributed
normally and were compared using the Mann-Whitney U test;.
Subject demographics and SCD characteristics were analyzed
with Chi-Square tests for categorical variables and either Student’s
t or Mann-Whitney U tests for continuous variables that were
normally or non-normally distributed, respectively. Mouse fibro-
cyte data were normally distributed and were compared using
Student’s t test. Paired measurements were compared using
Wilcoxon matched-pairs signed-ranks test. Probability values were
considered statistically significant if they were less than 0.05. Data
analysis was performed in SAS version 9.1 (SAS Institute, Cary,
NC).
The Institutional Review Board (IRB) at Washington University
and the University of Virginia approved all human protocols and
written informed consent was obtained in accordance with the
Declaration of Helsinki. IRB approval numbers are
PRO00014330 and 15598. The animal studies were carried out
in accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
Health and were approved by the Committee on the Ethics of
Animal Experiments of the University of Virginia (Permit
Number: 3549).
Refer to Supplemental Information S1 for detailed methods.
Results
Fibrocytes are markedly elevated and activated in the
circulation of patients with SCD at baseline
Since previous studies had demonstrated that elevated fibrocytes
can be found in the circulation of patients with ILD [23,25], we
wanted to determine whether fibrocytes were present in patients
with SCD under similar conditions (i.e., routine clinic visit with no
clinical evidence of VOC). From a cohort of patients with SCD at
Table 1. Baseline demographics, SCD characteristics and fibrocyte levels in SCD subjects with severe SCD phenotypes (HbSS/Sb-
thalassemia
0) compared to milder SCD phenotypes (HbSC/Sb-thalassemia
+).
SCD cohort
n=114
HbSS/Sbthal
0
n=82
HbSC/Sbthal
+
n=32 P value
Demographics
Age, median (IQR) 30.9 (17) 28.5 (14) 39.3 (21) 0.03
Gender, % male 46 47 44 0.28
SCD characteristics
Hemogloblin (g/dL), mean (SD) 9.1 (1.8) 8.5 (1.4) 10.5 (1.8) ,0.001
WBC (cells/mL), mean (SD) 11.2 (3.3) 11.7 (3.2) 9.8 (3.1) 0.004
LDH (IU/L), median (IQR) 311 (194) 360 (231) 244 (102) ,0.001
Hydroxyurea, % 33 44 6 ,0.001
Supplemental oxygen, % 19 26 3 0.006
Fibrocytes/ml610
5, median (IQR)
CD45+Col1+ 3.47 (6.78) 3.58 (6.90) 2.63 (6.28) 0.49
CD45+Col1+CXCR4+ 2.25 (6.15) 2.30 (6.54) 2.05 (6.18) 0.71
CD45+Col1+CCR2+ 0.68 (1.54) 0.66 (1.67) 0.74 (1.58) 0.98
CD45+Col1+CCR7+ 0.45 (1.46) 0.45 (1.55) 0.43 (1.14) 0.68
CD45+Col1+aSMA+ 0.58 (1.81) 0.66 (1.90) 0.56 (1.58) 0.93
CD45+Col1+pSMAD2/3+ 1.05 (3.56) 1.05 (3.75) 1.02 (3.51) 0.62
IQR, inter-quartile range; LDH, lactate dehydrogenase; SCD, sickle cell disease; SD, standard deviation; WBC, white blood cell.
doi:10.1371/journal.pone.0033702.t001
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SCD patients along with 19 African American controls were
collected and shipped overnight to the laboratory at UVA (RMS).
Mean age was 34612 years for the SCD cases and 4164 years for
the controls. Fifty-four percent of the SCD subjects were female,
whereas 88% of the control participants were female. Among the
SCD cases, 73% percent had HbSS or HbSbeta-thalassemia
0; the
remainder had HbSC and HbSbeta-thalassemia
+. Nineteen
percent of SCD subjects required home oxygen either continu-
ously or at night. When subjects with more and less severe SCD
phenotypes were compared (HbSS/HbSb-thalassemia
0 vs.
HbSC/HbSb-thalassemia
+), there were no differences in circulat-
ing fibrocyte levels (Table 1).
We assessed de novo the circulating levels of fibrocytes
(CD45+Col1+ cells) in these patients using quantitative FACS
analysis as previously described [23,25]. We chose to first gate on
CD45+ rather than CD34+ cells, because we have historically
found that the number of CD34+Col1+ fibrocytes in the
circulation is an order of magnitude lower than CD45+Col1+
fibrocytes (data not shown). Fibrocyte levels were significantly
higher in SCD cases compared to controls (median: 3.47610
5
cells/ml vs. 1.49610
5 cells/ml; p=0.001) (Figure 1A). Further
analysis of SCD cases demonstrated a hierarchy of chemokine
receptor expression (CXCR4&CCR2.CCR7) (Figure 1B, 1C,
and 1D). While tissue myofibroblasts can arise from cells other
than fibroytes, prior literature indicated that in both in vitro
studies and animal models, fibrocytes represent a progenitor cell
that can differentiate into aSMA-expressing myofibroblast-like
cells [13,29,30] and human lungs contain fibrocytes expressing the
myofibrobast marker aSMA [24]. We therefore also determined
whether the elevation in circulating fibrocytes in the SCD patients
was associated with increased numbers of aSMA+ fibrocytes in
circulation by quantitative FACS analysis as previously described
[23,25,30]. SCD patients had a higher number of aSMA+
fibrocytes compared to controls (Figure 1E). We previously
determined that TGF-b stimulation of fibrocytes via activation
of receptor Smads (Smad2/3) is critical to initiate signal
transduction and induction of aSMA in these cells [29]. On this
Figure 1. Fibrocytes are markedly elevated and activated in the circulation of patients with SCD at baseline compared to healthy
African American controls. A) fibrocytes defined as CD45+Col1+ cells were elevated in number in the circulation of patients with SCD, as
compared to control subjects. B–D) demonstrates that fibrocytes in the circulation of patients with SCD, as compared to control subjects express a
chemokine receptor hierarchy (i.e., CXCR4+.CCR2+.CCR7+). E–F) demonstrates that fibrocytes in the circulation of patients with SCD, as compared
to control subjects represent an activated phenotype of aSMA+ and pSmad2/3+ cells, respectively, compatible with fibrocytes pre-systemically
activated by TGF-b.
doi:10.1371/journal.pone.0033702.g001
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receptor Smads (pSmad2/3) by quantitative FACS analysis, which
we confirmed by using Western Blot analysis of cells stimulated
with TGF-b. Fibrocytes in circulation of SCD patients were
subsequently analyzed for activated receptor Smads (pSmad2/3)
and were found to be significantly higher than controls (Figure 1F).
Fibrocytes increase significantly over baseline level in
patients with SCD under conditions of VOC
Blood from 9 SCD patients were analyzed at baseline and at
time of admission to the hospital for VOC. Average age in this
subset of patients was 3569 years. Six subjects were female and 7
had HbSS/Sb-thalassemia
0. Notably, there were no significant
differences in age, gender, SCD genotype or baseline fibrocyte
levels between those SCD subjects with and without paired
measurements (data not shown). During a vaso-occlusive episode
compared to baseline, there were significant increases the number
of circulating fibrocytes (p=0.021), aSMA+ fibrocytes (p=0.008),
and pSmad2/3+ fibrocytes (0.015) (Figure 2A–C).
NY1DD SCD mice demonstrated increased deposition of
extracellular matrix in their lungs under baseline
conditions
To more fully elucidate the role of fibrocytes in the development
of ILD among patients with SCD, we next focused our studies on a
murine model of SCD [31]. Prior studies have shown that
significant injury from microvascular occlusion occurs during
baseline conditions in the NY1DD mouse, including lung injury
[31]. Since the NY1DD mice displayed evidence for marked lung
injury under baseline conditions, we sought evidence of pulmonary
fibroproliferation. Using the Sircol assay as previously described
[13,32] to measure total soluble collagen in the lungs of NY1DD
mice at 6 to 8 weeks; we determined that these mice have
increased levels of soluble collagen in their lungs, as compared
to controls (Figure 3A). These findings were confirmed by
morphometric analysis of the lungs by the collagen-specific dye
picrosirius red (Figure 3B). To put into context the levels of
soluble collagen in the lungs of these SCD mice with other mouse
models of pulmonary fibrosis, we compared these lung soluble
Figure 2. Fibrocytes increase significantly over baseline level in patients with SCD under conditions of VOC. A) Fibrocytes defined as
CD45+Col1+ cells in nine SCD patients were markedly increased from baseline during an episode of VOC. B–C) demonstrates that the fibrocytes in the
circulation of SCD patients undergoing a VOC represent an activated phenotype of aSMA+ and pSmad2/3+ cells, respectively, compatible with
fibrocytes systemically pre-activated by TGF-b.
doi:10.1371/journal.pone.0033702.g002
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bleomycin for 16 days to produce pulmonary fibrosis [32,33].
Levels of soluble collagen in bleomycin-exposed mice were similar
to the baseline levels of soluble collagen in the lungs of NY1DD
mice (Figure 3A).
NY1DD SCD mice displayed increased numbers of
fibrocytes in their bone marrow, circulation, and lungs
under baseline conditions
To determine whether the pathogenesis of increased fibropro-
liferation in the lungs of the NY1DD mice was due to the pre-
sence of fibrocytes, we next assessed the quantitative levels of
fibrocytes in the bone marrow, circulation (i.e., buffy coat cells),
and lungs of these animals, as compared to controls. Fibrocytes
were markedly expanded in the bone marrow, increased in the
circulation, and increased in the lungs of NY1DD mice (Figure 4A,
4B, and 4C, respectively). The same chemokine receptor hierarchy
was found on fibrocytes from the bone marrow, circulation,
and lungs, CXCR4&CCR2.CCR7 (Figure 4A, 4B, and 4C,
respectively). To further confirm that these were fibrocytes and not
macrophages that had phagocytized collagen, FACS analysis
was performed on these same cells to detect intracellular
pro-collagen type I and III by using specific antibodies that
detect the C-terminus and N-terminus of type I pro-collagen
and the C-terminus of pro-collagen III. CD45+ pro-collagen type I
and III positive cells were expanded in the bone marrow,
increased in the circulation and lungs of NY1DD mice
(Figure 4D, 4E, and 4F, respectively). In addition, we found
increased numbers of fibrocytes that appeared to be undergoing
differentiation to aSMA+ cells in the bone marrow, circulation,
and lungs of NY1DD SCD mice (Figure 4G, 4H, and 4I,
respectively).
NY1DD SCD mice displayed increased numbers of
fibrocytes in their bone marrow, circulation, and lungs
under conditions simulating VOC (hypoxia followed by
reoxygenation)
To determine whether NY1DD SCD mice experience worsen-
ing of their chronic ILD with hypoxia followed by reoxygenation
(normoxia) similar to patients with SCD that experience VOC, we
placed NY1DD SCD mice and wild type (C57BL/6) mice in
hypoxia (8% oxygen) for 3 hrs followed by return to normoxia
for 4 hrs using a modification as previously described [31].
Hypoxia followed by reoxygenation in NY1DD SCD mice
resulted in marked worsening histopathology of the lungs of
NY1DD SCD (Figure 5A and 5B), as compared to normoxic-
exposed mice, consisting of areas of fibrosis and inflammation.
These findings recapitulated what we had found in our previous
studies using this mouse model of SCD [31]. To determine
whether the marked change in pathology under conditions of
hypoxia/reoxygenation was associated with a change in the
number of fibrocytes, we measured fibrocytes under the above
conditions in the bone marrow, circulation, and lungs of these
mice. We found a marked increase in numbers of fibrocytes in the
bone marrow, circulation, and lungs under conditions of hypoxia
followed by normoxia, as compared to NY1DD SCD mice
exposed only to normoxia or to control mice (Figure 5C, 5D, and
5E, respectively). The chemokine receptor hierarchy that was
found expressed on fibrocytes under these conditions in the bone
marrow, circulation, and lungs demonstrated the persistent
expression pattern of CXCR4&CCR2.CCR7 (Figure 5C, 5D,
and 5E, respectively).
NY1DD SCD mice have increased lung levels of CXCL12
and other cytokines that are relevant to fibrocyte biology
On the basis of the presence of increased fibrocytes expressing
CXCR4 as the predominant chemokine receptor in the lungs of
NY1DD mice under either baseline or hypoxia/normoxic
conditions, we next determined whether CXCL12, the putative
ligand to CXCR4, was elevated in the lungs of NY1DD mice
under baseline conditions. We found that CXCL12 in lung
homogenates of NY1DD mice is markedly elevated and similar
to the levels of CXCL12 that we had found in bleomycin exposed
lungs on days 8 to 20, which also correlated with maximal
extracellular matrix deposition in this model (Figure 6A)
[13]. Immunohistochemistry for CXCL12 in the lungs of
NY1DD mice demonstrated that CXCL12 was localized to a
variety of cells in the lung parenchyma that included type II
pneumocytes. Moreover, when we measured other cytokines
thought to be relevant to fibrocyte biology [34,35], we found
elevated levels of PDGF and M-CSF in the lungs of these animals
(Figure 6B).
Figure 3. NY1DD SCD mice demonstrated increased deposition
of extracellular matrix in their lungs under baseline conditions.
A) NY1DD SCD mice, as compared to appropriate strain (C57Bl/6) and
age-matched mice, demonstrate elevated levels of total collagen in
their lungs under baseline (normoxia) conditions. The levels of total
collagen in the lungs of NY1DD mice at baseline are equivalent to
C57Bl/6 mice exposed to the pulmonary fibrotic agent, bleomycin, at
day 16. B) NY1DD mice, as compared to appropriate strain and age-
matched mice demonstrate elevated levels of collagen, as assessed by
morphometric analysis of picrosirius red staining of lung tissue. N=six
mice in each group. * p,0.05.
doi:10.1371/journal.pone.0033702.g003
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33702Figure 4. NY1DD SCD mice displayed increased numbers of fibrocytes in their bone marrow, circulation, and lungs under baseline
conditions. A–C) demonstrates that fibrocytes are elevated in the bone marrow, circulation, and lungs of NY1DD SCD mice, as compared to strain
and age-matched control mice. In addition, A–C) demonstrates that fibrocytes in the bone marrow, circulation, and lungs of NY1DD mice, as
compared to strain and age-matched mice express a chemokine receptor hierarchy (i.e., CXCR4+&CCR2+.CCR7+). D–F) demonstrates that elevated
fibrocytes in the bone marrow, circulation, and lungs of NY1DD mice, as compared to appropriate strain and age-match mice express pro-collagens I
and III (pro-collagen type I N and C-terminus=PINP and PICP, respectively; pro-collagen type III C-terminus=PIIICP). G–I) NY1DD SCD mice displayed
increased numbers of fibrocytes (CD45+Col1+ cells) in their bone marrow, circulation, and lungs under baseline conditions that represent an
activated phenotype (aSMA+ cells) compared to appropriate strain and age-match mice. N=six mice in each group. * p,0.05.
doi:10.1371/journal.pone.0033702.g004
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NY1DD SCD mice reduces the number of fibrocytes, and
this is correlated with a reduction in collagen deposition
and improvement in lung compliance and
histopathology
On the basis of the presence of CXCL12 in the lungs of
NY1DD mice under homeostatic conditions that directly corre-
lated with the presence of increased numbers of CXCR4+
fibrocytes, we next examined whether depletion of CXCL12
would impact on extravasation of fibrocytes into the lungs of
NY1DD mice, and whether this would have a direct effect on the
magnitude of collagen deposition. NY1DD mice under baseline
conditions were treated with neutralizing anti-CXCL12 or control
antibodies (i.p. Q48 hrs) for a period of 7 days at which point they
were sacrificed and their lungs assessed for levels of fibrocytes by
quantitative FACS and soluble collagen by the Sircol assay as
previously described [13,30]. We found a marked attenuation of
CD45+Col1+CXCR4+ fibrocytes in the lungs of the NY1DD
mice that had been depleted of CXCL12 (Figure 7A), which
directly correlated with a reduction in soluble collagen (Figure 7B).
Moreover, when we assessed the impact of this therapeutic
strategy on other populations of leukocytes in the lungs of these
mice, we found no significant impact on CD4, CD8, NK cells,
Figure 5. NY1DD SCD mice displayed marked lung fibrosis and inflammation under conditions simulating VOC (hypoxia followed
by reoxygenation) (B), as compared to NY1DD mice exposed to normoxic conditions alone (A). Photomicrographs are representative
H&E of lungs from six mice in each group, under 4006. NY1DD SCD mice displayed increased numbers of fibrocytes in their bone marrow, circulation,
and lungs under conditions simulating VOC (hypoxia followed by reoxygenation). C–E) demonstrates that fibrocytes are elevated in the bone marrow,
circulation, and lungs of NY1DD SCD mice under conditions simulating VOC (hypoxia followed by reoxygenation), as compared to NY1DD mice
exposed to normoxic conditions alone. In addition, C–E) demonstrates that fibrocytes in the bone marrow, circulation, and lungs of NY1DD SCD mice
under conditions simulating VOC (hypoxia followed by reoxygenation), as compared to NY1DD mice exposed to normoxic conditions alone express a
chemokine receptor hierarchy (i.e., CXCR4+&CCR2+.CCR7+). N=six mice in each group. * p=,0.05.
doi:10.1371/journal.pone.0033702.g005
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the lungs of NY1DD mice are undergoing collagen deposition
under baseline conditions that appears to be related to
extravasation of CXCR4+ fibrocytes into their lungs. In
conjunction with these studies we measured lung compliance
(i.e., using FlexiVent) under both conditions of closed chest and
open diaphragm and found that blocking CXCL12 resulted in
improved lung compliance (Figure 7C and 7D) that was associated
with markedly less ILD histopathology (Figure 7E and 7F).
Discussion
This study provides the first evidence that circulating
CD45+Col I+CXCR4+ fibrocytes, recruited through the
CXCL12/CXCR4 axis, contribute to the expansion of the
fibroblast/myofibroblast-like cell population in people and mice
with SCD. At baseline, NY1DD mice have increased fibrocytes in
the bone marrow, circulation and lungs compared to controls and,
similar to studies of subjects with IPF, the fibrocytes express the
hierarchy of chemokine expression CXCR4&CCR2.CCR7.
The CXCR4 ligand, CXCL12, is critical to CXCR4+ fibrocyte
trafficking and neutralizing CXCL12 prevents fibrocyte extrava-
sation into the lungs. These findings in NY1DD mice complement
our initial findings in adult patients with SCD providing
preliminary evidence for a role for fibrocytes in the development
of human ILD.
The pathogenesis of ILD in patients with SCD is poorly
understood. Previously, ILD in this patient population was thought
to be solely the result of repetitive infarcts occurring during ACS
episodes [2]. Recently, a new paradigm has emerged for the
understanding of vascular occlusion and end-organ damage in
SCD, suggesting that SCD should be viewed as a disease
characterized by subclinical, ongoing microvascular occlusion
and punctuated by clinically apparent exacerbations [31,36,37]. In
this model of SCD pathogenesis, end organ damage in SCD
results from the total injury that occurs from clinical exacerbations
plus ongoing, subclinical events. The findings of this study
demonstrating organ damage and elevated levels of circulating
fibrocytes at baseline in NY1DD mice support this notion of
chronic microvascular occlusion, systemic inflammation and
ongoing injury and repetitive repair, and provide a novel
mechanism for the understanding of lung fibroproliferation in
chronic ILD in patients with SCD.
Since the initial observations of ILD in patients with SCD were
published [2], newer data describing the role of nitric oxide
depletion, hemolysis and pulmonary hypertension in pathogenesis
of SCD has emerged [4,5]. In a prior study, Powars et al describe
chronic sickle cell lung disease as a disorder characterized by
pulmonary fibrosis, pulmonary hypertension and a mean survival
of 5 years [2]. More recently, several large studies have
demonstrated an increased risk of death associated with pulmo-
nary hypertension in adults with SCD [5,38,39]. Potentially, the
mortality risk associated with chronic sickle cell lung disease in the
prior study was due to pulmonary hypertension and not
pulmonary fibrosis. However, examining the etiology of ILD in
patients with SCD is important, because ILD has been shown to
contribute to the development of pulmonary hypertension in SCD
[40]. Although the findings in current study implicate fibrocytes in
the pathogenesis of ILD, future studies should focus on the
potential role of fibrocytes in the vascular remodeling of
pulmonary hypertension in SCD.
Circulating fibrocytes contribute to the fibroproliferation in the
lung seen in NY1DD mice. At baseline, there is increased collagen
deposition in the lung of NY1DD mice compared to control mice
demonstrating the active fibroproliferation in the lungs of NY1DD
mice. In the bone marrow, circulation and lungs of NY1DD mice,
fibrocytes are increased compared to controls and there is a
subpopulation of aSMA+ cells, consistent with a fibroblast/
myofibroblast-like cell. Although we cannot define the lineage of
aSMA+ cells based on our data, the presence of elevated aSMA+
fibrocytes in the bone marrow of NY1DD mice suggests that these
cells are beginning to undergo differentiation to a fibroblast/
myofibroblast-like cells in the bone marrow. Consistent with our
findings of CXCR4 predominance on circulating fibrocytes in
other mouse models of pulmonary fibrosis [23,24], the majority of
fibrocytes in NY1DD mice express CXCR4. The only known
ligand for CXCR4, CXCL12, was markedly elevated in the lungs
of NY1DD mice compared to controls, and neutralizing CXCL12
attenuated extravasation of fibrocytes into the lungs of NY1DD
mice and reduced lung collagen deposition. Taken together, these
findings support the notion that, at baseline, fibrocytes are
expanded in the bone marrow, mobilized to the circulation, home
Figure 6. NY1DD SCD mice have increased lung levels of CXCL12 and other cytokines that are relevant to fibrocyte biology. A)
demonstrates that the ligand to CXCR4, CXCL12, is markedly elevated in the lungs of NY1DD mice under baseline conditions compared to
appropriate strain and age-match mice. B) demonstrates that the growth factor (PDGF) and colony stimulating factor (M-CSF) are significantly
elevated in the lungs of NY1DD mice under baseline conditions compared to appropriate strain and age-match mice. N=six mice lungs in each
group. * p=,0.05.
doi:10.1371/journal.pone.0033702.g006
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CXCR4/CXCL12 chemokine axis.
In NY1DD mice, fibrocytes increase during hypoxia/reoxy-
genation compared to levels during normoxic conditions.
Although no animal model fully recapitulates human disease,
inducing hypoxia in NY1DD mice is thought to be analogous
to a VOC in patients with SCD [31,36]. Given that the natural
history of SCD is characterized by disease exacerbations or VOC
[41], hypoxia/reoxygenation in the mouse model approximates
human disease. The current data suggest that VOC causes
increased fibrocyte mobilization into circulation in both human
SCD and the mouse model, and potentially promotes increased
lung fibrosis.
Similar to findings in the NY1DD mouse, fibrocytes are
elevated at baseline in patients with SCD compared to healthy
control subjects. The chemokine hierarchy of
CXCR4&CCR2.CCR7 was also present in patients with
SCD, suggesting that the CXCR4/CXCL12 chemokine axis is
used for fibrocyte trafficking. Although circulating CXCL12 was
higher in patients with SCD compared to controls, this did not
reach statistical significance. CXCL12 was only measured in a
subset of our patients and this may have limited our ability to
Figure 7. Depletion of CXCL12 under baseline conditions in NY1DD SCD mice reduces the number of fibrocytes within their lungs,
and this is correlated with a reduction in collagen deposition and improvement in lung compliance and histopathology. A)
demonstrates that passive immunization of NY1DD mice with anti-CXCL12, as compared to appropriate control F(ab)2 antibodies markedly
attenuates the presence of fibrocytes in the lungs of NY1DD mice under baseline conditions. B) demonstrates that passive immunization of NY1DD
mice with anti-CXCL12, as compared to appropriate control F(ab)2 antibodies reduces the amount of soluble collagen in the lungs of NY1DD mice
under baseline conditions. C–D) demonstrates that passive immunization of NY1DD mice with anti-CXCL12, as compared to appropriate control
F(ab)2 antibodies improves the compliance of the lungs of NY1DD mice under baseline conditions. E–F) demonstrates that passive immunization of
NY1DD mice with anti-CXCL12 (F), as compared to appropriate control F(ab)2 antibodies (E) improves the histopathology of the lungs as
demonstrated by the H&E photomicrographs. N=six mice in each group for A–D, lung photomicrographs (E–F) are representative of six lungs from
each group. * p=,0.05.
doi:10.1371/journal.pone.0033702.g007
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should be the site for elevated levels of CXCL12 in order to
promote a ‘‘chemotactic gradient’’ for CXCR4+ fibrocytes; and
we found elevated levels of CXCL12 in the lungs of NY1DD mice.
However, since plasma levels of CXCL12 were not significantly
different between SCD subjects and controls, we can only
postulate that in human SCD the CXCR4/CXCL12 chemokine
axis and the gradient of CXCL12 in the lung is responsible for
fibrocyte homing. During a VOC, fibrocyte levels within SCD
subjects increased significantly over baseline and demonstrated an
activated phenotype. Repeat measurements within an individual
using a longitudinal study design provides assurance that the
findings are not due to inter-individual variation. Our study was
not designed to determine cause and effect between VOC and
fibrocyte levels in patients with SCD. We can only report an
association. Regardless of whether vaso-occlusion causes increased
fibrocyte levels or vice versa, higher levels of fibrocytes in
association with VOC may promote fibroproliferation and end
organ damage. These data are consistent with NY1DD mice and
support the notion that disease exacerbations (i.e., VOC)
significantly contribute to the development of end organ disease.
Furthermore, these data provide preliminary evidence that the
pathophysiology and pathology we found in the NY1DD mouse
can be translated to patients with SCD.
Taken together, our data in NY1DD mice and supported by
evidence in patients with SCD suggests a novel model of ILD
pathogenesis in SCD. This new paradigm for understanding the
mechanism of pulmonary fibrosis in SCD implicating bone-
marrow-derived fibrocytes is consistent with findings in IPF. Based
on the data from this study, we postulate that inflammatory
‘‘signals’’ (i.e., CXCL12) generated in the lung communicate with
the bone marrow leading to expansion of fibrocytes. The condition
of vaso-occlusion (i.e., either subclinical or VOC) in the bone
marrow creates an environment that is hypoxic in nature, which
favors the induction of CXCR4 expression on fibrocytes that
ultimately enhances their homing and extravasation at the target
organ site (i.e., lung) in response to CXCL12. These circulating
fibrocytes, largely CXCR4+, will only home and extravasate into
an end-organ (i.e., lung) if there is the appropriate ‘‘address’’
signal, such as lung-specific expression of a chemokine ligand (i.e.,
CXCL12) to CXCR4. Once fibrocytes home and extravasate into
the lung dependent on the CXCL12/CXCR4 biological axis, the
data from our NY1DD mice suggests that they play a major role in
functioning as mesenchymal progenitor cells for the production of
extra-cellular matrix and contribution to fibrosis in the lungs of
patients with SCD.
In summary, our results provide a new basis for understanding
the pathogenesis of ILD in patients with SCD, a common and
serious complication in this patient population [2,3,6]. The
findings of our study offer the opportunity to therapeutically
target fibrocytes by attenuating their recruitment into the lung in
order to prevent pulmonary fibrosis.. Future studies are needed to
examine strategies to attenuate fibrocytes and determine the
impact on the longitudinal development of ILD in patients with
SCD.
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